Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Huang, Lynn Y ^a   Lee, Ying Shuan ^b   Huang, Jiann Jyh ^b   Chang, Chia Chi ^a   Chang, Jia Ming ^b   Chuang, Shih Hsien ^b   Kao, Kuo Jang ^a   Tsai, Yung Jen ^b   Tsai, Pei Yi ^b   Liu, Chia Wei ^b   Lin, Her Sheng ^b   Lau, Johnson Y ^a  

^a Taivex Therapeutics Corporation   (Taiwan)

^b DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

Anti cancer drug; Apoptosis; Hec1; Markers for response; Mitosis; NDC80; P53; Retinoblastoma gene; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOXORUBICIN; NDC80 COMPLEX; PACLITAXEL; POTASSIUM CHANNEL HERG; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; SORAFENIB; TAI 1; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BODY WEIGHT; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL SPECIFICITY; CHROMOSOME ABERRATION; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIVER CANCER; METAPHASE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NIACINAMIDE; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; RETINOBLASTOMA PROTEIN; THIAZOLES; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892154921     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-6     Document Type: Article

References (29)

1. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Harrison MR, Holen KD, Liu G, Clin Ad Hematol Oncol: H&O 2009 7 54 64
2. Recent advances of kinesin motor inhibitors and their clinical progress. Voultsiadou A, Sarli V, Rev Recent Clin Trials 2011 6 271 277 10.2174/157488711796575522 21682672
3. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH, Cancer Res 2008 68 8393 8399 10.1158/0008-5472.CAN-08- 1915 18922912
4. Expression of the kinetochore protein Hec1 during the cell cycle in normal and cancer cells and its regulation by the pRb pathway. Ferretti C, Totta P, Fiore M, Mattiuzzo M, Schillaci T, Ricordy R, Di Leonardo A, Degrassi F, Cell Cycle 2010 9 4174 4182 10.4161/cc.9.20.13457 20948316
5. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R, Proc Natl Acad Sci U S A 2008 105 16719 16724 10.1073/pnas.0803504105 18940925
6. The Ndc80 complex: hub of kinetochore activity. Ciferri C, Musacchio A, Petrovic A, FEBS Let 2007 581 2862 2869 10.1016/j.febslet.2007.05.012
7. Phosphorylation of the Ndc80 complex protein, Hec1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Wei R, Ngo B, Wu G, Lee WH, Mol Biol cell 2011 22 3584 3594 10.1091/mbc.E11-01-0012 21832156
8. Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. Val IC C d, Almeida Filho GL, Valiante PM, Gondim C, Takiya CM, Carvalho Mda G, J Reprod Med 2004 49 868 874 15603096
9. Expression and clinical significance of highly expressed protein in cancer (Hec 1) in human primary gallbladder carcinoma. Xiao GF, Tang HH, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008 24 910 912 18782526
10. RNA interference against Hec1 inhibits tumor growth in vivo. Gurzov EN, Izquierdo M, Gene Ther 2006 13 1 7 10.1038/sj.gt.3302595 16121206
11. The application of p53 gene mutation status in fecal specimen in the diagnosis of colorectal carcinoma. Zhan Q, Yan J, Jiang ZY, Si J, Chen T, Guo JZ, Tao GQ, Zhonghua Nei Ke Za Zhi 2004 43 502 505 15312403
12. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. Qiu XL, Li G, Wu G, Zhu J, Zhou L, Chen PL, Chamberlin AR, Lee WH, J Med Chem 2009 52 1757 1767 10.1021/jm8015969 19243176
13. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G, Chembiochem 2002 3 455 459 10.1002/1439-7633(20020503)3: 5<455::AID-CBIC455>3.0.CO;2-L 12007180
14. Use of in vitro methods to predict QT prolongation. Hammond TG, Pollard CE, Toxicol Appl Pharmacol 2005 207 446 450 10.1016/j.taap.2005.03.022 16023163
15. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG, Breast Cancer Res Treat 2012 132 391 409 10.1007/s10549-011-1513-3 21509526
16. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, Akula B, Hoffman BS, Reddy E, J Med Chem 2011 54 6254 6276 10.1021/jm200570p 21812421
17. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES, J Clin Invest 2007 117 218 228 10.1172/JCI28803 17160137
18. RB activation defect in tumor cell lines. Broceno C, Wilkie S, Mittnacht S, Proc Natl Acad Sci U S A 2002 99 14200 14205 10.1073/pnas.212519499 12379745
19. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, Xie D, Zhuang L, Deng J, Ma D, Clin Cancer Res 2005 11 8431 8440 10.1158/1078-0432.CCR-05-1085 16322306
20. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, Ozturk M, FASEB J 1993 7 1407 1413 8224613
21. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH, Clin Cancer Res 1999 5 2596 2604 10499638
22. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Iborra F, et al. Mol Cell Biol 2006 26 7561 7574 10.1128/MCB.00605-06 17015477
23. p53 and breast cancer, an update. Lacroix M, Toillon RA, Leclercq G, Endocr Relat Cancer 2006 13 293 325 10.1677/erc.1.01172 16728565
24. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T, Cancer Biol Ther 2008 7 699 708 10.4161/cbt.7.5.5712 18277095
25. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M, Breast Cancer Res Treat 2006 99 97 101 10.1007/s10549-006-9186-z 16541312
26. Regulation of p53 protein expression in human breast cancer cell lines. Vojtesek B, Lane DP, J Cell Sci 1993 105 Pt 3 607 612 8408290
27. Identification and classification of p53-regulated genes. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B, Proc Natl Acad Sci U S A 1999 96 14517 14522 10.1073/pnas.96.25.14517 10588737
28. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Stahler F, Roemer K, Oncogene 1998 17 3507 3512 10030675
29. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Durfee T, Becherer K, Chen PL, Yeh SH, Yang Y, Kilburn AE, Lee WH, Elledge SJ, Genes Dev 1993 7 555 569 10.1101/gad.7.4.555 8384581